Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model

References

• Shields C, Shields J. Recent developments in the manage-ment of retinoblastoma. J Pediatr Ophthalmol Strabismus.1999;36:8–18.
   PubMedGoogle Scholar
• Shields CL, Shields JA, De Potter P New treatment modal-ities for retinoblastoma. Curr Opin Ophthalmol.1996;7: 20–26.
   PubMedGoogle Scholar
• Chan H, Thomer P, Haddad G, Gallie B. Multidrug resistant phenotype in retinoblastoma correlates with P-glycoprotein expression. Ophthalmology.1991 ;98: 1425–1431.
   PubMed Web of Science ®Google Scholar
• Kingston J, Hungerford J, Madreperla S, Plowman P Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol.1996;114:1339–1343.
   PubMedGoogle Scholar
• Murphree AL, Villablanca JG, Deegan WF, Salo JK, Malogolowkin M, Fisher A, Parker R, Reed E, Gomer CJ. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol.1996;114: 1348–1356.
   Google Scholar
• Gallie B, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, Ling P, Chan HS. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radio-therapy. Arch Ophthalmol.1996;114:1321–1328.
   PubMed Web of Science ®Google Scholar
• Schueler A, Jurklies C, Heimann H, Wieland R, Havers W, Bornfeld N. Thermochemistry in hereditary retinoblas-toma. Br J Ophthalmol.2003;87:90–95.
   PubMedGoogle Scholar
• Grostern RJ, Bryar P, Zimbric M, Soesiawati D, Lissauer B, Lindstrom M, Lokken J, Strugnell S, Albert DM. Toxicity and dose-response studies of lalpha-hydroxyvitamin D2 in a retinoblastoma xenograf t model. Arch Ophthalmol.2002;120: 607–612.
   Google Scholar
• Sabet S, Djaratmoko S, Lindstrom M, Albert DM. Anti-neoplastic effect and toxicity of 1,25-dihydroxy-16-ene-23-yne-vitamin D in athymic mice with Y79 human retinoblastoma tumors. Arch Ophthalmol.1999 ;117 :365–370.
   PubMed Web of Science ®Google Scholar
• Shternfeld IS, Lasudry JG, Chappell RJ, Darjatmoko SR, Albert DM. Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma. Arch Ophthalmol.1996;114: 1396–1401.
   Google Scholar
• Wilkerson C, Darjatmoko S, Lindstrom M, Albert DM. Toxicity and dose response studies of 1,25(OH)2-16ene-23yne vitamin D3 in transgenic mice. Clin Cancer Res.1998;4:2253–2256.
   PubMedGoogle Scholar
• Brandt C, Imesch P, Robinson N, Syed S, Untawale S, Darjatmoko S, Chappell R, Heinzelman P, Albert DM. Treatment of spontaneously arising retinoblastoma tumors in transgenic mice with an attenuated herpes simplex virus mutant. Virology.1997a;229:283–291.
   Google Scholar
• Kogishi J, Miyatake S, Hangai M, Akimoto M, Okazaki K, Honda Y. Mutant herpes simplex virus-mediated suppres-sion of retinoblastoma. Curr Eye Res.1999;18:321–326.
   PubMed Web of Science ®Google Scholar
• Nicolo M, Chiocca E. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res.1997;30:30–36.
   Google Scholar
• Hurwitz M, Marcus K, Chevez-Barrios P, Louie K, Aguilar-Cordova E, Hurwitz RL. Suicide gene therapy for treatment of retinoblastoma in a murine model. Hum Gene Ther.1999;10:441–448.
   PubMed Web of Science ®Google Scholar
• Markert TM, Gillespie GY, Weichselbaum RR, Roadman B, Whitley RJ. Genetically engineered HSV in the treatment of glioma: A review. Rev Med Virol.2000;10:17–30.
   Google Scholar
• Burton E, Wechuck J, Wendell S, Goins W, Fink D, Glorioso J. Multiple applications for replication-defective Herpes simplex virus vectors. Stem Cells.2001;19:358–377.
   PubMedGoogle Scholar
• Mineta T, Rabkin S, Martuza RL. Treatment of malignant gliomas using gancyclovir-hypersensitive, ribonucleotide reductase-deficient Herpes simplex viral mutants. Cancer Res.1994;54:3963–3966.
   Google Scholar
• Macleod KF, Jacks T. Insights into cancer from transgenic mouse models. J Pathol.1999;187:43–60.
   PubMed Web of Science ®Google Scholar
• Windle J, Albert DM, O'Brien J, Marcus DM, Disteche CM, Bernards R, Mellon PL. Retinoblastoma in transgenic mice. Nature.1990;343:665–669.
   Google Scholar
• O'Brien J, Marcus D, Bernards R, Carpenter J, Windle J, Mellon PD, Albert D. A transgenic model for trilateral retinoblastoma. Arch Ophthalomol.1990;108:1145–1151.
   PubMedGoogle Scholar
• Albert DM, Marcus D, Gallo J, O'Brien J. The antineo-plastic effect of vitamin D in transgenic mice with retinoblastoma. Invest Ophthalmol Vis Sci.1992;33:2343–2364.
   Google Scholar
• Cameron JM, McDougall I, Marsden HS, Preston VG, Ryan DM, Subak-Sharpe JH. Ribonucleotide reductase encoded by Herpes simplex virus is a determinant of the pathogenicity of the virus in mice and a valid antiviral target. J Gen Virol.1988;69:2607–2612.
   Google Scholar
• Jacobson J, Leib D, Goldstein D, Bogard C, Schaffer P, Weller S, Coen D. A Herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replica-tion in mouse cells. Virology.1989;173:276–283.
   Google Scholar
• Brandt CR, Kintner RL, Pumfery AM, Visalli RJ, Grau DR. The Herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol.1991;72:2043–2049.
   Google Scholar
• Brandt CR, Imesch P, Spencer B, Eliassi-Rad B, Untawale S, Robinson N, Albert D. The Herpes simplex virus type 1 ribonucleotide reductase is required for acute retinal disease. Arch Virol.1997b;142: 883–896.
   Google Scholar
• Goldstein D, Weller SK. Factor(s) present in Herpes simplex virus type-1 infected cells can compensate for the loss of the large subunit of the viral ribonulceotide reduc-tase: Characterization of an ICP6 deletion mutant. Virology.1988;166:41–51.
   PubMed Web of Science ®Google Scholar
• Grau DR, Visalli RJ, Brandt CR. Herpes simplex virus stromal keratitis is not titer-dependent and does not cor-relate with neurovirulence. Invest Ophthalmol Vis Sci.1989;30:2474–2480.
   Google Scholar
• Thompson RL, Wagner EK, Stevens JG. Physical location of a Herpes simplex virus type-1 gene function(s) specifi-cally associated with a 10 million-fold increase in HSV neurovirulence. Virology.1983;131: 180–192.
   Google Scholar
• Spencer B, Agarwala S, Gentry L, Brandt CR. HSV-1 vector-delivered FGF2 to the retina is neuroprotective, but does not preserve functional responses. Mol Ther.2001;3:746–756.
   PubMedGoogle Scholar
• Brandt C, Grau D. Mixed infection with herpes simplex virus Type 1 generates recombinants with increased ocular and neurovirulence. Invest Ophthalmol Vis Sci.1990;31: 2214–2223.
   PubMed Web of Science ®Google Scholar
• Boviatsis E, Scharf J, Chase M, Harrington K, Kowall N, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with Herpes simplex virus vectors defective in thymidine kinase and ribonucleotide reductase. Gene Ther.1994;1: 323–331.
   Google Scholar
• Kramm C, Chase M, Herrlinger U, Jacobs A, Pechan P, Rainov N, Sena-Esteves M, Aghi M, Chiocca EA, Breakefield XO. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors. Hum Gene Ther.1997;8:2057–2068.
   Google Scholar
• Kayusa H, Nishiyama Y, Nomoto S, Hosono J, Takeda S, Nakao A. Intraperitoneal delivery of hrR3 and gancyclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol.1999;72:136–141.
   PubMedGoogle Scholar
• Yoon S, Nakamura H, Carroll N, Bode B, Chiocca EA, Tanabe K. An oncolytic Herpes simplex virus type 1 selec-tively destroys diffuse liver metastases from colon carci-noma. FASEB J2000;14:301–311.
   PubMed Web of Science ®Google Scholar
• Howes K, Lausdry J, Albert D, Windle J. Photoreceptor tumors in transgenic mice. Invest Ophthalmol Vis Sci.1994;35:342–351.
   PubMedGoogle Scholar
• Mills M, Windle J, Albert DM. Retinoblastoma in trans-genic mice: Models of hereditary retinoblastoma. Surv Ophthalmol.1999;43:508–518.
   Google Scholar
• Ferris F, Chew E. A new era for the treatment of retinoblas-toma. Arch Ophthalmol.1996;114:1412.
   PubMedGoogle Scholar
• Brandt CR, Kintner R, Pumfery A, Visalli RJ, Grau DR. The Herpes simplex virus ribonucleotide reductase is required for ocular virulence. J Gen Virol.1991;72: 2043–2049.
   Google Scholar
• Whitley RJ, Kern ER, Chatterjee S, Chou J, Roizman B. Replication, establishment of latency, and induced reactivation of herpes simplex virus 7134.5 deletion mutants in rodent models. J Clin Invest.1993;91: 2387–2843.
   Google Scholar
• Bolovan CA, Sawtell N, Thompson RL. ICP34.5 mutants of herpes simplex virus Type-I strain 17syn+ are attenuated for neurovirulence in mice and for replication in confluent primary mouse embryo cultures. J Virol.1994;68: 48–55.
   Google Scholar